SHE: 300482

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran
CompanyDeals

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran

Merck KGaA (ETR: MRK) announced that it has entered into a definitive agreement to acquire Silence Therapeutics plc (NASDAQ: SLN), a UK‑headquartered global clinical‑stage biotechnology company pioneering siRNA therapies in…

AbbVie's Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn's Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

AbbVie’s Dual‑Targeting ABBV‑466 Outperforms Both Monotherapies in Crohn’s Disease – Higher Endoscopic Remission Rates at Week 12 in TARGET‑CD Study

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Wondfo Biotech's MSI Detection Kit Granted NMPA Marketing Clearance
CompanyMedical Device

Wondfo Biotech’s MSI Detection Kit Granted NMPA Marketing Clearance

CompanyDeals

Wondfo Biotech and University of Science, Malaysia Deepen Ties with Formal Partnership

CompanyMedical Device

Andon Health’s Triplex Virus Test Kit Receives US FDA Emergency Use Authorization

CompanyMedical Device

Wondfo Biotech’s WELLlife Test Kit Receives FDA Nod for Home Use in the US

CompanyDeals

Guangzhou Wondfo Biotech Partners with Indonesia’s Kimia Farma in IVD Field